Li XiaoRui, Huo XiaoQing, Li WeiWei, Yang QingHui, Wang Ying, Kang XiaoChun
Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China,
Tumour Biol. 2014 Dec;35(12):11959-65. doi: 10.1007/s13277-014-2489-5. Epub 2014 Nov 17.
Cyclin D1 polymorphism has been reported to be associated with risk of breast cancer, but the published studies have yielded controversial results. This study was undertaken to derive a precise risk estimate for the cyclin D1 polymorphism associated with breast cancer risk. We performed a search of EMBASE, PubMed, and Web of Science. In total, data from 18 publications were pooled and the association was assessed by odds ratios (ORs) with 95 % confidence intervals (CIs). This analysis showed that there was no obvious association between the cyclin D1 polymorphism and breast cancer risk in any of the analyzed genetic model. We found the same negative association in stratified analyses by ethnicity, source of controls, and sample size. Our meta-analysis provides an estimate that the presence of cyclin D1 polymorphism may not confer susceptibility to breast cancer.
细胞周期蛋白D1多态性据报道与乳腺癌风险相关，但已发表的研究得出了相互矛盾的结果。本研究旨在得出与乳腺癌风险相关的细胞周期蛋白D1多态性的精确风险估计值。我们检索了EMBASE、PubMed和科学网。总共汇总了18篇出版物的数据，并通过比值比（OR）及95%置信区间（CI）评估关联。该分析表明，在任何分析的遗传模型中，细胞周期蛋白D1多态性与乳腺癌风险之间均无明显关联。我们在按种族、对照来源和样本量进行的分层分析中发现了相同的负相关。我们的荟萃分析提供了一个估计值，即细胞周期蛋白D1多态性的存在可能不会使人易患乳腺癌。
